Quality control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group

被引:19
|
作者
Favalli, G
Vermorken, JB
Vantongelen, K
Renard, J
Van Oosterom, AT
Pecorelli, S
机构
[1] Univ Antwerp Hosp, Dept Med Oncol, B-2650 Edegem, Belgium
[2] Univ Brescia, Spedali Civili, Dept Gynecol Oncol, Brescia, Italy
[3] Univ Hosp Gasthuisberg, Dept Oncol, B-3000 Louvain, Belgium
[4] Eortc Data Ctr, Brussels, Belgium
关键词
quality control; multicentric trials; chemotherapy;
D O I
10.1016/S0959-8049(00)00090-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data Quality is a central requirement of scientific research and external monitoring is essential in multicentric clinical trials (MCT). A quality control (QC) study was conducted in the main Institutions participating in EORTC-GCCG Protocol number 55863 - randomised phase III trial of vindesine. cisplatin, bleomycin and mitomycin-C (BEMP) versus cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix - in order to assess the impact of variations in data quality on the conclusions of the trial. The reliability of the different centres in following the protocol was investigated by a questionnaire covering drug prescription, local facilities and the procedure for preparation and administration of chemotherapy. The 'treatment protocol adherence' was evaluated by recalculation of the ideal protocol dose and its comparison with the actual delivered dosage at each cycle of chemotherapy. 'Data quality control' was assessed by comparison of data on case report forms (CRFs) with the corresponding items in the medical records. Eleven centres participating in the trial were visited by the same team of reviewers. Striking differences were noted in the chemotherapy administration procedures and between the type and quality of hospital files. Overall. there was an acceptable level of data quality and protocol compliance. Data accuracy was 81.8% (range: 65.6-97%) of the 4424 items checked. Incorrect data were found in 7.0% (2.3-14.5%), data were missing on the form in 3.6% of cases (0-12%) and data was on the form but not in the file in 7.6% of cases (0.7-17.5%). Causes of inaccuracy were analysed. Both problems in data management but also in a lack of clarity of the protocol and/or CRFs were to blame. Training and supervision of data managers, precision in writing protocols, standardisation of some aspects of CRFs and the use of a checklist for chemotherapy data and treatment toxicities would have avoided many of these errors. The need for QC in all collaborative groups performing MCT is emphasised. A literature review on QC in MCT dealing with chemotherapy is included. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1125 / 1133
页数:9
相关论文
共 50 条
  • [31] Optimized production and quality control of 68Ga-EDTMP for small clinical trials
    Mirzaei, Alireza
    Jalilian, Amir R.
    Badbarin, Ali
    Mazidi, Mohammad
    Mirshojaei, Fatemeh
    Geramifar, Parham
    Beiki, Davood
    ANNALS OF NUCLEAR MEDICINE, 2015, 29 (06) : 506 - 511
  • [32] Reducing Errors in Clinical Trials: The Importance of Acknowledging Human Error and Improving Quality Control
    Mayer, Megan
    Govil, Preetika
    Ricciardi, Francesca
    Melnitsky, Jayda
    Peleg, Shannon
    Kantrowitz, Joshua
    BIOLOGICAL PSYCHIATRY, 2024, 95 (10) : S287 - S288
  • [33] Optimized production and quality control of 68Ga-EDTMP for small clinical trials
    Alireza Mirzaei
    Amir R. Jalilian
    Ali Badbarin
    Mohammad Mazidi
    Fatemeh Mirshojaei
    Parham Geramifar
    Davood Beiki
    Annals of Nuclear Medicine, 2015, 29 : 506 - 511
  • [34] Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials
    Lorusso, Domenica
    Mainenti, S.
    Ferrandina, G.
    Scambia, G.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 987 - 991
  • [35] Assessment of Factors That Contribute to Decreased Quality of Life in Gynecologic Oncology Group Ovarian Cancer Trials
    von Gruenigen, Vivian E.
    Huang, Helen Q.
    Gil, Karen M.
    Gibbons, Heidi E.
    Monk, Bradley J.
    Rose, Peter G.
    Armstrong, Deborah K.
    Cella, David
    Wenzel, Lari
    CANCER, 2009, 115 (20) : 4857 - 4864
  • [36] Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: A randomized phase II trial of the EORTC lung cancer cooperative group
    Manegold, C
    Drings, P
    Pawinski, A
    Lentz, MA
    vanGlabbeke, M
    vanZandwijk, N
    Bachmann, P
    Schnaars, Y
    Skacel, Z
    Zatloukal, P
    Dolensky, J
    Jackevicius, A
    Petruzelka, L
    Giaccone, G
    ANNALS OF ONCOLOGY, 1996, 7 (06) : 637 - 639
  • [37] Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials A Systematic Review and Meta-analysis
    Yang, Fang
    Markovic, Svetomir N.
    Molina, Julian R.
    Halfdanarson, Thorvardur R.
    Pagliaro, Lance C.
    Chintakuntlawar, Ashish, V
    Li, Rutian
    Wei, Jia
    Wang, Lifeng
    Liu, Baorui
    Nowakowski, Grzegorz S.
    Wang, Michael L.
    Wang, Yucai
    JAMA NETWORK OPEN, 2020, 3 (08)
  • [38] Establishing professional phlebotomist group for quality control of the preanalytic variables of clinical laboratory
    Wang, Haijuan
    Liu, Xiaojuan
    Kuang, Linghan
    Shi, Hua
    Jiang, Yongmei
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (10) : 1841 - 1842
  • [39] Sleep Quality and Quality of Life in Breast Cancer Patients: Comparative Study with a Healthy Control Group
    Ilhan, Yusuf
    Balcik, Onur Yazdan
    Karadag, Ibrahim
    Almuradova, Elvina
    JOURNAL OF TURKISH SLEEP MEDICINE-TURK UYKU TIBBI DERGISI, 2024, 11 (02):
  • [40] Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials
    Argiris, A.
    Li, S.
    Ghebremichael, M.
    Egloff, A. M.
    Wang, L.
    Forastiere, A. A.
    Burtness, B.
    Mehra, R.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1410 - 1416